• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

IntelliCell BioSciences inks research agreement with Rutgers’ N.J. Center for Biomaterials

November 28, 2012
CenterWatch Staff

IntelliCell BioSciences, a regenerative medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs, has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers, the state university of New Jersey.

The New Jersey Center for Biomaterials will be conducting a series of research projects that will further define the unique characteristics and properties of IntelliCell's proprietary cellular population. The work will be conducted on behalf of IntelliCell under the direction of professor Joachim Kohn, a researcher and director of the New Jersey Center for Biomaterials.

Initial research will focus on documenting any differences between IntelliCell's proprietary cellular population and similar cell populations isolated from human adipose tissue using conventional methods of cell isolation. After successful completion of the initial phases of the clinical research, the company hopes to engage the New Jersey Center for Biomaterials in development projects that may lead to bioengineered products containing the proprietary IntelliCell cellular population and products under development at the New Jersey Center for Biomaterials.

"This is a truly exciting opportunity for us. We have a number of highly advanced scaffolds for regenerative therapies (e.g. re-growing bone, nerve and skin), and we expect that IntelliCell's cell populations will significantly enhance the effectiveness of our biomaterials-based scaffolds,” said Kohn. “In this collaborative research project, we are combining the outstanding cell biology expertise of IntelliCell with the expertise of our chemists and materials scientists.  We believe that through this collaboration, we will be able to demonstrate the merits of interdisciplinary research efforts between industry and academia.” 

Kohn added, “In addition, emerging companies like IntelliCell are the main driving force for health care innovation, and we are delighted to assist such companies with technologies under development."

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing